Guillermo De Velasco, MD, PhD, University Hospital 12 de Octubre, Madrid, Spain, presents the results of the CABOPRE study (NCT04022343), a Phase II study of cabozantinib prior to cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (mRCC). Dr De Velasco reports that 1 out of 4 patients achieved partial response to this treatment and that cabozantinib showed statistically significant improvements for patients in all endpoints of this trial, and notably in median progression-free survival (PFS) where patients reached a median PFS of 12.7 months. In addition, this study helped identify which patients should undergo cytoreductive nephrectomy and predict which patients could benefit from treatment with cabozantinib. Finally, Dr De Velasco outlines ongoing analyses on the role of microRNAs (miRNA) in predicting treatment responses. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.